Prudential Financial Inc. Acquires 1,010 Shares of Retrophin Inc (NASDAQ:RTRX)

Prudential Financial Inc. lifted its position in Retrophin Inc (NASDAQ:RTRX) by 0.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 253,099 shares of the biopharmaceutical company’s stock after purchasing an additional 1,010 shares during the period. Prudential Financial Inc. owned about 0.61% of Retrophin worth $5,084,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Envestnet Asset Management Inc. raised its position in shares of Retrophin by 3.3% in the 2nd quarter. Envestnet Asset Management Inc. now owns 18,698 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 592 shares during the last quarter. State Board of Administration of Florida Retirement System raised its holdings in shares of Retrophin by 2.8% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 27,335 shares of the biopharmaceutical company’s stock worth $549,000 after acquiring an additional 740 shares in the last quarter. Altshuler Shaham Ltd raised its holdings in shares of Retrophin by 3.3% during the 2nd quarter. Altshuler Shaham Ltd now owns 34,583 shares of the biopharmaceutical company’s stock worth $695,000 after acquiring an additional 1,116 shares in the last quarter. Swiss National Bank raised its holdings in shares of Retrophin by 2.5% during the 2nd quarter. Swiss National Bank now owns 69,400 shares of the biopharmaceutical company’s stock worth $1,394,000 after acquiring an additional 1,700 shares in the last quarter. Finally, Strs Ohio raised its holdings in shares of Retrophin by 7.4% during the 2nd quarter. Strs Ohio now owns 34,700 shares of the biopharmaceutical company’s stock worth $697,000 after acquiring an additional 2,400 shares in the last quarter.

RTRX traded up $0.40 on Friday, hitting $12.13. 15,481 shares of the company traded hands, compared to its average volume of 1,097,598. The company has a 50 day moving average of $16.12 and a 200-day moving average of $19.45. The company has a quick ratio of 4.99, a current ratio of 5.05 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $514.16 million, a PE ratio of -4.68 and a beta of 0.92. Retrophin Inc has a 12-month low of $11.39 and a 12-month high of $30.21.

Retrophin (NASDAQ:RTRX) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.27). The business had revenue of $44.71 million for the quarter, compared to analysts’ expectations of $43.01 million. Retrophin had a negative return on equity of 47.21% and a negative net margin of 83.94%. The business’s quarterly revenue was up 8.2% on a year-over-year basis. During the same period last year, the company posted ($0.25) earnings per share. On average, research analysts anticipate that Retrophin Inc will post -4.03 EPS for the current year.

In other news, insider Noah L. Rosenberg sold 2,500 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $19.95, for a total transaction of $49,875.00. Following the sale, the insider now owns 14,750 shares in the company, valued at $294,262.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.32% of the stock is owned by company insiders.

RTRX has been the topic of several research analyst reports. BMO Capital Markets cut their price objective on Retrophin from $38.00 to $33.00 and set an “outperform” rating on the stock in a research report on Friday, August 23rd. ValuEngine raised Retrophin from a “hold” rating to a “buy” rating in a research report on Wednesday, September 4th. BidaskClub cut Retrophin from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 27th. Zacks Investment Research upgraded Retrophin from a “sell” rating to a “hold” rating in a research note on Wednesday, July 10th. Finally, William Blair restated a “buy” rating on shares of Retrophin in a research note on Friday, August 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. Retrophin currently has a consensus rating of “Buy” and an average price target of $29.71.

Retrophin Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

See Also: Overbought

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.